FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate – Trademark Portfolio

Entity Type: 99

FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The owner is based in Cologne.

Gereonsmühlengasse 1-11

Cologne 50670 , DE

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

FACILIDO
FACILIDO
Abandoned 2012
GLYDO
GLYDO
Abandoned 2010
ENDOSTIL
ENDOSTIL
Abandoned 2010
JELUBRIA
JELUBRIA
Abandoned 2010

Trademark Classifications

FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate have?

FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate has 5 U.S. trademarks filed with the USPTO.

What trademark classes does FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate file in?

FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate's trademark registration success rate?

FARCO-Pharma Gesellschaft mit beschränkter Haftung Pharmazeutische Präparate has a 0% trademark registration rate, with 0 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.